Treatment of onychomycosis: An update

A. Shirwaikar, T. Thomas, A. Shirwaikar, R. Lobo, K.S. Prabhu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.
Original languageEnglish
Pages (from-to)710-714
Number of pages5
JournalIndian Journal of Pharmaceutical Sciences
Volume70
Issue number6
DOIs
Publication statusPublished - 2008

Fingerprint

Onychomycosis
Mycoses
Antifungal Agents
Nails
Fungi
Lacquer
Skin
Arthrodermataceae
Toes
Infection
Scalp
Fingers
Foot
Hand
Yeasts

Cite this

Shirwaikar, A., Thomas, T., Shirwaikar, A., Lobo, R., & Prabhu, K. S. (2008). Treatment of onychomycosis: An update. Indian Journal of Pharmaceutical Sciences, 70(6), 710-714. https://doi.org/10.4103/0250-474X.49088
Shirwaikar, A. ; Thomas, T. ; Shirwaikar, A. ; Lobo, R. ; Prabhu, K.S. / Treatment of onychomycosis: An update. In: Indian Journal of Pharmaceutical Sciences. 2008 ; Vol. 70, No. 6. pp. 710-714.
@article{1cdfe9b6d97b46f7a00985f5d51933ad,
title = "Treatment of onychomycosis: An update",
abstract = "Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.",
author = "A. Shirwaikar and T. Thomas and A. Shirwaikar and R. Lobo and K.S. Prabhu",
note = "Cited By :5 Export Date: 10 November 2017 CODEN: IJSID Correspondence Address: Shirwaikar, A. A.; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal 576104, India; email: arunshirwaikar@yahoo.co.in Chemicals/CAS: amorolfine, 78613-38-4; ciclopirox, 29342-05-0; ciclopiroxolamine, 41621-49-2; erythromycin, 114-07-8, 70536-18-4; fluconazole, 86386-73-4; griseofulvin, 126-07-8; itraconazole, 84625-61-6; ketoconazole, 65277-42-1; terbinafine, 91161-71-6 Tradenames: diflucan; fulvicin; gifulvin; gris peg; lamisil; penlac; sporanox References: Cohen, P.R., Scher, R.K., Aging (1999) Atlas of hair and nails, pp. 213-225. , Hordinsky MK, Sawaya ME, Scher RK, editors, Philadelphia: Churchill Livingstone;; Roberts, D.T., Taylor, W.D., Boyle, J., Guidelines for treatment of onychomycosis (2003) Br J Dermatol, 148, pp. 402-410; Nathan, A., Treatment of fungal nail infection (2006) Pharm J, 276, pp. 597-600; Iorizzo, M., Piraccini, B.M., Rech, G., Tosti, A., Treatment of onychomycosis with oral antifungal agents (2005) Expert Opin Drug Deliv, 2, pp. 435-440; Gupta, A.K., Schouten, J.R., Lynch, L.E., Ciclopirox nail lacquer 8{\%} for the treatment of onychomycosis: A Canadian perspective (2005) Skin Ther Lett, 10, pp. 1-3; Practice guidance: OTC Amorolfine nail lacquer. London: Royal Pharmaceutical Society of Britain; 2006; Drug Evaluation Monographs, Micromedex, Inc. 76 Exp. (May 31, 1993); Tosti, A., Piraccini, B.M., Lorenzi, S., Iorizzo, M., Treatment of non dermatophyte mold and candida onchomycosis (2003) Dermatol Clin, 21, pp. 491-497; http://www.fda.gov, Available from; http://www.guideline.gov, Available fromUR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-64349104450&doi=10.4103{\%}2f0250-474X.49088&partnerID=40&md5=78f034b13dc229b20eb93ae4eeac7d9c",
year = "2008",
doi = "10.4103/0250-474X.49088",
language = "English",
volume = "70",
pages = "710--714",
journal = "Indian Journal of Pharmaceutical Sciences",
issn = "0250-474X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "6",

}

Shirwaikar, A, Thomas, T, Shirwaikar, A, Lobo, R & Prabhu, KS 2008, 'Treatment of onychomycosis: An update', Indian Journal of Pharmaceutical Sciences, vol. 70, no. 6, pp. 710-714. https://doi.org/10.4103/0250-474X.49088

Treatment of onychomycosis: An update. / Shirwaikar, A.; Thomas, T.; Shirwaikar, A.; Lobo, R.; Prabhu, K.S.

In: Indian Journal of Pharmaceutical Sciences, Vol. 70, No. 6, 2008, p. 710-714.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of onychomycosis: An update

AU - Shirwaikar, A.

AU - Thomas, T.

AU - Shirwaikar, A.

AU - Lobo, R.

AU - Prabhu, K.S.

N1 - Cited By :5 Export Date: 10 November 2017 CODEN: IJSID Correspondence Address: Shirwaikar, A. A.; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal 576104, India; email: arunshirwaikar@yahoo.co.in Chemicals/CAS: amorolfine, 78613-38-4; ciclopirox, 29342-05-0; ciclopiroxolamine, 41621-49-2; erythromycin, 114-07-8, 70536-18-4; fluconazole, 86386-73-4; griseofulvin, 126-07-8; itraconazole, 84625-61-6; ketoconazole, 65277-42-1; terbinafine, 91161-71-6 Tradenames: diflucan; fulvicin; gifulvin; gris peg; lamisil; penlac; sporanox References: Cohen, P.R., Scher, R.K., Aging (1999) Atlas of hair and nails, pp. 213-225. , Hordinsky MK, Sawaya ME, Scher RK, editors, Philadelphia: Churchill Livingstone;; Roberts, D.T., Taylor, W.D., Boyle, J., Guidelines for treatment of onychomycosis (2003) Br J Dermatol, 148, pp. 402-410; Nathan, A., Treatment of fungal nail infection (2006) Pharm J, 276, pp. 597-600; Iorizzo, M., Piraccini, B.M., Rech, G., Tosti, A., Treatment of onychomycosis with oral antifungal agents (2005) Expert Opin Drug Deliv, 2, pp. 435-440; Gupta, A.K., Schouten, J.R., Lynch, L.E., Ciclopirox nail lacquer 8% for the treatment of onychomycosis: A Canadian perspective (2005) Skin Ther Lett, 10, pp. 1-3; Practice guidance: OTC Amorolfine nail lacquer. London: Royal Pharmaceutical Society of Britain; 2006; Drug Evaluation Monographs, Micromedex, Inc. 76 Exp. (May 31, 1993); Tosti, A., Piraccini, B.M., Lorenzi, S., Iorizzo, M., Treatment of non dermatophyte mold and candida onchomycosis (2003) Dermatol Clin, 21, pp. 491-497; http://www.fda.gov, Available from; http://www.guideline.gov, Available fromUR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-64349104450&doi=10.4103%2f0250-474X.49088&partnerID=40&md5=78f034b13dc229b20eb93ae4eeac7d9c

PY - 2008

Y1 - 2008

N2 - Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.

AB - Fungal infections of skin are one of the most common infections in human beings. The areas which are likely to get infected include the scalp, the hands and the feet. Dermatophytes, yeasts and moulds are the three major fungi responsible for skin infections. Earlier oral antifungal agents were used for treatment of fungal infection in finger and toe nails. The disadvantages of oral antifungal agents are toxicity and longer treatment period. Now medicated nail lacquers have been developed for the treatment of fungal infections i.e. onychomycosis, which has less toxicity and shorter treatment period.

U2 - 10.4103/0250-474X.49088

DO - 10.4103/0250-474X.49088

M3 - Article

VL - 70

SP - 710

EP - 714

JO - Indian Journal of Pharmaceutical Sciences

JF - Indian Journal of Pharmaceutical Sciences

SN - 0250-474X

IS - 6

ER -